SSA
KITE

Schonfeld Strategic Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-30,966
Closed -$2.43M – 874
2017
Q1 		$2.43M Buy
+30,966
New +$1.91M 0.24% 119
2016
Q3 		– Sell
-11,413
Closed -$571K – 619
2016
Q2 		$571K Buy
+11,413
New +$561K 0.13% 208

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Schonfeld Strategic Advisors's KITE Position: Q2 2017 in Review

Schonfeld Strategic Advisors sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 30,966 shares — an estimated $2.43M sold.

Schonfeld Strategic Advisors first reported a position in KITE in Q2 2016 and held it in 2 quarters. The position peaked at $2.43M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

  • Schonfeld Strategic Advisors reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 30,966 Kite Pharma, Inc. shares in Q2 2017, an estimated $2.43M.
  • Schonfeld Strategic Advisors first reported a position in Kite Pharma, Inc. in Q2 2016 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Kite Pharma, Inc. position peaked at $2.43M in Q1 2017.
  • 220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.